Oak Hill Bio
Focus: Oak Hill Bio is a UK-based biotechnology company focused on small molecules targeting protein misfolding diseases, with a pipeline spanning rare genetic and neonatal indications. As a public-stage biotech, the company operates at modest scale with limited disclosed headcount.
Profile data last refreshed 8h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Oak Hill Bio?
AI assessmentOak Hill Bio is a speculative opportunity for rare-disease specialists seeking deep portfolio involvement, but limited hiring and undisclosed financials present career-risk unless you have high tolerance for biotech stage risk.
Why Work Here
- Rare disease focus (Angelman Syndrome, Bronchopulmonary Dysplasia, Retinopathy of Prematurity) offers deep scientific impact and differentiated portfolio positioning
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Help build intelligence for Oak Hill Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.